China Lists PVH Group and Illumina as Unreliable Entities with Far-Reaching Implications
On February 4, China announced that it has included the American PVH Group and Illumina, Inc. on its unreliable entity list. This decision has garnered significant attention, signaling escalating tensions in Sino-U.S. trade relations.
The announcement stated that both companies violated normal market trading principles, disrupted regular transactions with Chinese enterprises, and adopted discriminatory measures against them, severely harming the legitimate rights and interests of Chinese businesses. The mechanism for the unreliable entity list will take corresponding actions against these entities in accordance with relevant laws and regulations to safeguard the legitimate interests of Chinese enterprises.
The announcement emphasizes that the relevant measures will take effect immediately and any unspecified matters will be executed according to the Regulations on Unreliable Entities. This action is viewed as an important step by China in responding to external pressures and protecting its market.
In the context of global economic integration, this move could have profound implications for business relations between China and the U.S., potentially prompting other countries to reassess their cooperative ties with China. As the international market environment evolves, companies need to closely monitor policy developments to navigate potential challenges and opportunities.
Looking for chemical products? Let suppliers reach out to you!
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Faces a Compliance Test
-
India’s API Trade Balance Turns Positive
-
BioNTech’s Founders Turn the Page
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Rising API Costs Threaten Drug Prices
-
Lilly Bets Bigger on China
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
Recommend Reading
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Methanol market prices mainly on the rise in China
-
Methane Lewis Structure Explained: Step-by-Step Guide
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
The negative spread has widened, with acrylic acid prices continuously falling and showing weakness domestically in China
-
Weak Consumption Leads to Decline in ABS Prices in Mid-May in China